Edgardo S. Santos, MD, FACP, FCCP

The panel concludes the discussion with key takeaways on the evolving treatment landscape in HER2 non–small cell lung cancer.

Experts on HER2 NSCLC provide clinical insights on selecting between antibody-drug conjugates and TKIs, treatment sequencing, and the role of chemoimmunotherapy.

The expert panel shares its thoughts on current challenges and unmet needs in the overall HER2-mutated non–small cell lung cancer treatment landscape.

D. Ross Camidge, MD, PhD, discusses the main adverse events seen with TKIs in patients with HER2-mutated non–small cell lung cancer.

Martin Dietrich, MD, PhD, provides an overview of the first-in-human study of BAY2927088, a novel TKI, in patients with advanced HER2-mutated non–small cell lung cancer.

The panel offers comprehensive insights on the Beamion LUNG-1 clinical trial, which is investigating zongertinib in patients with advanced HER2-mutated non–small cell lung cancer.

Edward Kim, MD, MBA, describes the potential role of tyrosine kinase inhibitors (TKIs) in the treatment of patients with HER2-mutated non–small cell lung cancer.

Lyudmila A. Bazhenova, MD, an expert on non–small cell lung cancer, provides clinical insights on the management of adverse events associated with antibody-drug conjugates.

Edward S. Kim, MD, MBA, discusses the DESTINY-Lung04 trial, a study evaluating trastuzumab deruxtecan as first-line treatment for patients with HER2-mutated NSCLC.

Experts on HER2-mutated NSCLC discuss the patient populations in which they’d utilize trastuzumab deruxtecan and share their clinical experiences with the therapy.

Lyudmila A. Bazhenova, MD, and D. Ross Camidge, MD, PhD, review the DESTINY-Lung01 and DESTINY-Lung02 trials, and the panel provides its impressions of the data.

The panel discusses the role of antibody-drug conjugates (ADCs) and the treatment of patients with HER2-mutated non–small cell lung cancer.

Experts on HER2-mutated non–small cell lung cancer provide clinical insights on biomarker testing challenges and the role of reflex testing.

A panel of thoracic oncologists introduce themselves and discuss biomarker testing strategies and the diagnosis of HER2-mutated non–small cell lung cancer (NSCLC).

Dr Edgardo Santos highlights key takeaways from the presented data and provides insights into how these findings could shape the future landscape of healthcare directions.

Edgardo Santos, MD, FACP, FCCP, offers expert insights into the squamous subgroup analysis of EMPOWER-Lung1 and 3, shedding light on the implications of these data for the treatment of individuals with squamous non-small cell lung cancer (NSCLC).

Edgardo Santos, MD, FACP, FCCP, analyzes the influence on clinical practice arising from the application of cemiplimab with chemotherapy in advanced non-small cell lung cancer (NSCLC) observed in the EMPOWER-Lung3 trial.

Edgardo Santos, MD, FACP, FCCP, provides expert insights into the latest data from the TROPION-Lung01 trial, emphasizing the potential implications of this information for treating patients with non-actionable biomarkers in NSCLC.

Edgardo Santos, MD, FACP, FCCP, analyzes the recent developments in the DESTINY-Lung01 and DESTINY-Lung02 trials, specifically focusing on HER2+ NSCLC patients with brain metastases and exploring the potential impact on clinical practice.

Edgardo Santos, MD, FACP, FCCP, provides insights into the innovative Beamion Lung 1 trial, focused on assessing the safety and tolerability of zongertinib (BI 1810631) in patients with advanced, previously treated HER2+ non-small cell lung cancer (NSCLC).

Experts discuss the challenges of the ongoing cisplatin and carboplatin shortages in the United States and detail how they are adapting in their practices.

Edgardo S. Santos, MD, FACP, discusses key survival data from the pivotal phase 3 ADAURA trial in early-stage non–small cell lung cancer.

Edgardo Santos MD, FACP, FCCP, discusses how cancer centers across the United States are minimizing the negative effects of the ongoing carboplatin and cisplatin shortage, and details potential next steps that should be taken to prevent drug shortages like this from occurring in the future.

Edgardo Santos, MD, FACP, FCCP, discusses testing and treatment in NRG1 fusion–positive non–small cell lung cancer.

Edgardo Santos, MD, FACP, FCCP, clinical affiliate associate professor, Florida Atlantic University; treasurer, Florida Society of Clinical Oncology, discusses first-line treatment options for patients with ALK-positive non–small cell lung cancer.

Edgardo S. Santos, MD, FACP, discusses the evolution of osimertinib in the treatment of patients with EGFR-mutated non–small cell lung cancer and the updated data that reaffirmed its role in the adjuvant setting for this patient population.

Edgardo S. Santos, MD, FACP, discusses the impact of treatment with cemiplimab plus chemotherapy in patients with squamous non–small cell lung cancer.

Martin Dietrich, MD, PhD, and Edgardo Santos, MD, FACP, offer closing remarks on unmet needs and future directions in the management of CIM including other disease states where trilaciclib may offer myeloprotective benefit.

Focusing the discussion on the clinical trials that led to the FDA approval of trilaciclib, experts in ES-SCLC share key insights into the drug’s safety and its effect on patient quality of life.

Renowned leaders in thoracic oncology discuss efficacy data from key clinical trials that led to the FDA approval of the CDK4/6 inhibitor trilaciclib for CIM prophylaxis in ES-SCLC, including the drug’s role in later treatment lines.